Macrogenics (MGNX) EBIT Margin (2012 - 2026)

Macrogenics' (MGNX) quarterly EBIT Margin came in at 160.96% in Q1 2026, up 16215.0% year-on-year from N/an in Q1 2025, and down 448.55% on a QoQ basis from 29.34% in Q4 2025.

Macrogenics (MGNX) EBIT Margin (2012 - 2026) Analysis & Trends

Macrogenics (MGNX) has 15 years of EBIT Margin data on file, last reported at 160.96% in Q1 2026.

  • On a quarterly basis, EBIT Margin rose 16215.0% year-over-year to 160.96% in Q1 2026; TTM through Mar 2026 was 40.53%, a 1640.0% increase from a year earlier, with the FY2025 full-year figure at 48.72%, up 2501.0% from the prior year.
  • EBIT Margin for Q1 2026 stood at 160.96%, down from 29.34% in the prior quarter.
  • Over the last five years, EBIT Margin for MGNX reached as high as 48.95% in Q3 2024 and fell as low as 600.29% in Q1 2022.
  • Historically, EBIT Margin has averaged 233.59% across 5 years, with a median of 160.96% in 2026.
  • On a YoY basis, EBIT Margin climbed as much as 44342 bps in 2023 and fell as far as 47678 bps in 2023.
  • Year by year, EBIT Margin stood at 16.39% in 2022, then slumped by 2908 bps to 460.39% in 2023, then soared by 71 bps to 132.09% in 2024, then jumped by 78 bps to 29.34% in 2025, then slumped by 449 bps to 160.96% in 2026.
  • Per Business Quant data, the three most recent EBIT Margin figures were 160.96% in Q1 2026, 29.34% in Q4 2025, and 25.59% in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT Margin (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 16.51%
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 38.10%
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 17.83%
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 31.68%
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Macrogenics 254.43 Mn 187.92 Mn - -160.96%

Historic Data

Download Data
DateValue
Mar 31, 2026 -160.96%
Dec 31, 2025 -29.34%
Sep 30, 2025 25.59%
Jun 30, 2025 -165.27%
Mar 31, 2025 -323.10%
Dec 31, 2024 -132.09%
Sep 30, 2024 48.95%
Jun 30, 2024 -538.86%
Mar 31, 2024 -590.40%
Dec 31, 2023 -460.39%
Sep 30, 2023 -341.46%
Jun 30, 2023 -342.28%
Mar 31, 2023 -156.87%
Dec 31, 2022 16.39%
Sep 30, 2022 -59.80%
Jun 30, 2022 -160.76%
Mar 31, 2022 -600.29%
Dec 31, 2021 -411.65%
Sep 30, 2021 -338.32%
Jun 30, 2021 -130.96%